Danaher Corporation (DHR)
| Market Cap | 192.55B |
| Revenue (ttm) | 31.25B |
| Net Income (ttm) | 6.64B |
| Shares Out | 728.30M |
| EPS (ttm) | 9.05 |
| PE Ratio | 29.21 |
| Forward PE | 25.91 |
| Dividend | $1.00 (0.38%) |
| Ex-Dividend Date | Dec 29, 2022 |
| Volume | 2,514,146 |
| Open | 263.02 |
| Previous Close | 262.75 |
| Day's Range | 260.42 - 265.18 |
| 52-Week Range | 233.71 - 303.82 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 311.15 (+17.69%) |
| Earnings Date | Jan 24, 2023 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filt... [Read more]
Financial Performance
In 2021, Danaher's revenue was $29.45 billion, an increase of 32.17% compared to the previous year's $22.28 billion. Earnings were $6.27 billion, an increase of 78.60%.
Financial StatementsAnalyst Forecast
According to 30 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $311.15, which is an increase of 17.69% from the latest price.
News
Danaher: A Future-Focused Spinoff Value Play
In September 2022, Danaher Corp. ( DHR , Financial) announced its intention to spin off its environmental and applied solutions segment into a separate publicly traded business in the fourth quarter o...
Danaher (DHR) Q4 Earnings & Revenues Beat, Increase Y/Y
Danaher's (DHR) Q4 results benefit from strong segmental performances and organic sales growth.
Danaher Hit After Cutting Covid-Related Revenue From Growth Reports
The medical company's fourth-quarter earnings beat expectations, but analysts say investors are paying attention to other elements of the report.
Danaher (DHR) Tops Q4 Earnings and Revenue Estimates
Danaher (DHR) delivered earnings and revenue surprises of 16.67% and 9.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Danaher Reports Fourth Quarter and Full Year 2022 Results
WASHINGTON , Jan. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2022. All results in this release reflect only ...
HTHIY vs. DHR: Which Stock Is the Better Value Option?
HTHIY vs. DHR: Which Stock Is the Better Value Option?
Will Cost Headwinds Dampen Danaher's (DHR) Q4 Earnings?
High raw material costs and supply-chain disruptions are likely to have hurt Danaher's (DHR) Q4 earnings. However, the top line is likely to have benefited from an expected increase in revenues at the...
Analysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks Ron Baron and Daniel Loeb Agree On
Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) are two gurus that follow very different investing styles. While both focus on the long term, Baron's Baron Funds aims to invest in va...
Here's Why Hold Strategy is Apt for Danaher (DHR) Stock Now
Strength across the Life Sciences segment, inorganic activities and DBS initiatives bode well for Danaher's (DHR) growth. Shareholder-friendly policies add to the stock's appeal.
Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance
Benefiting from strong growth in Cepheid's molecular diagnostics among other factors, Danaher (DHR) improves its adjusted core revenue growth guidance for the fourth quarter of 2022.
Danaher sees Q4 sales increasing in ‘low-single-digit percent range'
Danaher Corp. DHR, +1.01% on Monday said it expected fourth-quarter sales to rise in the “low-single-digit percent range,” despite what executives said was a “challenging environment” for the maker of...
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 9, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compan...
Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer
OTTAWA, Canada--(BUSINESS WIRE)--Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be j...
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON , Jan. 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Why Danaher (DHR) Could Beat Earnings Estimates Again
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Multi-Sector Conglomerates Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Final Trades: American Water, Boeing, Danaher & more
The "Halftime Report" traders give their top picks to watch for the second half.
Danaher Schedules Fourth Quarter 2022 Earnings Conference Call
WASHINGTON , Dec. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 202...
Grade My Trade: SMH & DHR
The ‘Halftime Report' investment committee, Shannon Saccocia, Sarat Sethi, Joe Terranova and Jim Lebenthal, weigh in on the Danaher and semis trade.
Jim Cramer recommends these 5 healthcare stocks in 2023
Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.
Danaher (DHR) Up 14% in 6 Months: What's Driving the Stock?
Danaher (DHR) gains from strength across its core Life Sciences segment, benefits from the DBS initiatives and acquired assets. The company's efforts to add shareholder value hold promise.
Danaher Announces Quarterly Dividends
WASHINGTON , Dec. 6, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common st...
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 22, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...
Danaher (DHR) Just Reclaimed the 200-Day Moving Average
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?